The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents.
about
A scalable method for molecular network reconstruction identifies properties of targets and mutations in acute myeloid leukemiaRadotinib Induces Apoptosis of CD11b+ Cells Differentiated from Acute Myeloid Leukemia CellsIdentification and targeting leukemia stem cells: The path to the cure for acute myeloid leukemia.Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinicEffective co-delivery of doxorubicin and dasatinib using a PEG-Fmoc nanocarrier for combination cancer chemotherapyIs targeted therapy feasible in acute myelogenous leukemia?Src family kinases and their role in hematological malignancies.Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials.Relevance of leukemic stem cells in acute myeloid leukemia: heterogeneity and influence on disease monitoring, prognosis and treatment design.Aminoisoquinoline benzamides, FLT3 and Src-family kinase inhibitors, potently inhibit proliferation of acute myeloid leukemia cell lines.Therapeutic effects of dasatinib in mouse model of multiple sclerosis.Targeting cancer stem cell-specific markers and/or associated signaling pathways for overcoming cancer drug resistance.CD99 is a therapeutic target on disease stem cells in myeloid malignancies.Antileukemic effects of midostaurin in acute myeloid leukemia - the possible importance of multikinase inhibition in leukemic as well as nonleukemic stromal cells.Integrated analysis of proteome, phosphotyrosine-proteome, tyrosine-kinome, and tyrosine-phosphatome in acute myeloid leukemia.Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growthLyn, a tyrosine kinase closely linked to the differentiation status of primary acute myeloid leukemia blasts, associates with negative regulation of all-trans retinoic acid (ATRA) and dihydroxyvitamin D3 (VD3)-induced HL-60 cells differentiation.Epithelial ovarian cancer with CD117 phenotype is highly aggressive and resistant to chemotherapy.miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis.Myeloproliferative neoplasm with eosinophilia and T-lymphoblastic lymphoma with ETV6-LYN gene fusionTargeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death.Differential antigen expression and aberrant signaling via PI3/AKT, MAP/ERK, JAK/STAT, and Wnt/β catenin pathways in Lin-/CD38-/CD34+ cells in acute myeloid leukemia.Adhesion structures in leukemia cells and their regulation by Src family kinases.Dasatinib prevent hepatic fibrosis induced by carbon tetrachloride (CCl4) via anti-inflammatory and antioxidant mechanism.p53-dependent CD51 expression contributes to characteristics of cancer stem cells in prostate cancer.Selective inhibition of the myeloid Src-family kinase Fgr potently suppresses AML cell growth in vitro and in vivo.
P2860
Q24289222-BECED942-57FE-4BDD-969D-CC4CE8914372Q28548235-9C80366C-B90B-4846-BF4B-C6573BA5D3E0Q34232877-B69399D2-E1C7-47DA-A446-879F1BEB84C6Q34817365-A7B41713-21E0-4E7C-911C-6411D3049733Q35998388-C2887D9E-BD21-4A06-9A2D-F7C298321583Q36416358-E4F0F22E-C398-4762-ABD8-AF488F9F5ED4Q38217719-3AD10687-39BD-42A0-8EE0-B2C9FCC89C96Q38235929-510BE768-14F7-4BE5-A81F-FDB59DA9C04EQ38253011-C340152C-4742-4708-94BC-B3728D5FEFDCQ38685553-1A677567-FBDB-4A93-AEB0-33BCA701A6B0Q38874789-9B9FBAF1-120B-4B34-B3B9-68235C68AA0CQ38937280-A4FA43EE-4C30-466D-81AF-8467B958C74DQ38998882-D2BC301E-A2D1-4F2A-9C3C-EFA54B047916Q39045977-202066A8-1C85-491F-9F8D-6D21B2784D14Q40956513-79DB13B4-4615-4A49-BBE8-66C2BB546B7AQ41071486-01005519-EE59-45CE-B72E-28BA9F7F2B53Q41536100-27A932A0-7168-4A00-877A-1DD729E9DAEAQ41584097-FEDCFCF7-DEC2-4C35-8911-16176CC7F38FQ42082695-19603D76-7BA2-42B2-BB09-CBC15A212A98Q42837969-4794E208-E37E-494A-9A21-DBF909FEFB72Q46038713-DD2E310B-66CF-49D7-A9BA-CADD9F150676Q47929673-7DD3A008-8B55-49FC-A11B-965DFDC72AE4Q48174522-5803071D-0866-43BD-9E39-7BA075393345Q51033171-F00A78DD-70F3-424C-A34C-96AFBF805B65Q53685182-C65B93AF-0C70-4EC0-8601-620CA6F92EA1Q54109758-6C6B960B-4336-4709-B8AF-02C1114A4D6A
P2860
The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The Src and c-Kit kinase inhib ...... ls by chemotherapeutic agents.
@en
The Src and c-Kit kinase inhib ...... ls by chemotherapeutic agents.
@nl
type
label
The Src and c-Kit kinase inhib ...... ls by chemotherapeutic agents.
@en
The Src and c-Kit kinase inhib ...... ls by chemotherapeutic agents.
@nl
prefLabel
The Src and c-Kit kinase inhib ...... ls by chemotherapeutic agents.
@en
The Src and c-Kit kinase inhib ...... ls by chemotherapeutic agents.
@nl
P2093
P2860
P1433
P1476
The Src and c-Kit kinase inhib ...... ls by chemotherapeutic agents.
@en
P2093
Cedric Dos Santos
Hongjun Liu
Ravi Bhatia
Stephen J Forman
Tinisha McDonald
Ya-Huei Kuo
Yin Wei Ho
P2860
P304
P356
10.1182/BLOOD-2012-11-466425
P407
P577
2013-07-29T00:00:00Z